@MichaelMindrum how do patients get the coupon? wish they would just make it easy and straightforward for patients and skip the extra steps or paperwork...
@FedericaFogacci@society_eas@EASCongress this slide is perhaps overly optimistic, as FIELD primary endpoint was null and REDUCE-IT results were independent of triglycerides. The trig remnant story may not be as compelling as the Lp(a) story for CVD risk reduction but we will soon see...
@Ashwinreads One thing to mode is the cost of these agents will drop - with approval of Lerochol and likely approval of enlicitide. Other options will be approved over the next few years, likely causing further price deflation (?)
@patrick_oshag They are too expensive. Patients won't pay and coverage indications are narrow. When these factors change, uptake will be much higher as they are highly effective and virtually devoid of adverse effects.
Your editorial refers to Koreans as 'South Asians' (?). They are East Asians fyi. In fact, the Authors of the main paper use the term 'East Asian' throughout the Discussion section.
Also contrary to what is implied in the editorial, the study reported that creatinine levels were slightly LOWER in the study arm that received more intensive treatment so this was not a signal for harm. Probably not a notable finding nor of any clinical consequence, but still....
rather sloppy work....